Company Overview

Update
Headquarters:
Pasadena, CA
IPO:
Went Public on Oct 20, 2000
Stock:
NASDAQ:ARWR
Categories:
Biotechnology

Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.

Description

Update

Arrowhead Research Corporation, through its subsidiaries, identifies advances in nanotechnology and matches them with product development opportunities in high-growth markets, focusing on the electronics and biotech industries. It focuses on developing, commercializing, and licensing a range of nanotechnology products and applications, including anti-cancer drugs, RNAi therapeutics, regenerative therapeutics, advanced drug delivery technology, energy storage technology, carbon-based electronics, and fullerene anti-oxidants. The company has developed Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers. Its lead anti-cancer drug candidate IT-101 is a combination of Cyclosert and the potent anti-cancer drug, camptothecin, is under Phase I clinical trials. Arrowhead Research also focuses on the design, development, and commercialization of novel RNA... See More

Current Team (7)

Update

Board Members and Advisors (8)

Update

Investments (1)

Update

Funding Rounds (3) - $66M

Update

Investors (1)

Update
  • Bd8077886d711cf10064ab173defbc71

    RA Capital Management

    RA Capital Management is an investment advisor based in Boston specializing in the life-sciences..

Offices/Locations (1)

Update
  • Office

    201 South Lake Avenue

    Suite 703

    Pasadena, CA 91101

    USA

Images (1)

Update
  • 64ccc0b958975ed074eb857e980c12d5